Chemomab Therapeutics Ltd. (CMMB) NASDAQ
1.80
+0.08(+4.65%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.80
+0.08(+4.65%)
Currency In USD
| Previous Close | 1.72 |
| Open | 1.74 |
| Day High | 1.84 |
| Day Low | 1.71 |
| 52-Week High | 5.48 |
| 52-Week Low | 1.35 |
| Volume | 31,200 |
| Average Volume | 46,439 |
| Market Cap | 11.08M |
| PE | -1.61 |
| EPS | -1.12 |
| Moving Average 50 Days | 1.68 |
| Moving Average 200 Days | 2.22 |
| Change | 0.08 |
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 17, 2026 1:00 PM GMT
TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announce
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
GlobeNewswire Inc.
Dec 02, 2025 1:00 PM GMT
—New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a Phase 3 Registration Trial— TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Chemoma
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Nov 20, 2025 1:00 PM GMT
—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a Clinical Event Composite Endpoint— —Phase 2 SPRING Tria